MedTrace Logo

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT02010034 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-02-06

No results posted yet for this study

Summary

This study is being done to determine if an investigational study drug called Omegaven can help to improve liver disease thought to be caused by Total Parenteral Nutrition (TPN). TPN is intravenous feeding (IV feeding tube) that provides patients the nutrients when they are unable to drink fluid or eat food by mouth.

Conditions

  • Liver Disease
  • Impaired Liver Function
  • Parenteral Nutrition Associated Liver Disease

Interventions

DRUG

Omegaven

Omegaven will be used in place of soy oil Intralipid

Sponsors & Collaborators

  • Children's Medical Center Dallas

    lead OTHER

Principal Investigators

  • Nandini Channabasappa, MD · Childrens Health

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2019-02-05
Completion
2019-02-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02010034 on ClinicalTrials.gov